This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients
Khansa Ahsan, Munir Ahmad Anwar, Nayla Munawar
Khansa Ahsan, Nayla Munawar, Department of Chemistry, United Arab Emirates University, Al Ain 15551, United Arab Emirates
Munir Ahmad Anwar, Industrial Biotechnology Division, National Institute for Biotechnology and Genetic Engineering College, Pakistan Institute of Engineering and Applied Sciences (NIBGE-C, PIEAS), Faisalabad 38000, Pakistan
Author contributions: Ahsan K performed data acquisition, the majority of the writing, and prepared the figures; Anwar MA wrote a section, reviewed, and edited; Munawar N conceptualized the manuscript, designed the outline and figures, wrote the abstract, and provided major input in writing and guidance in the investigation of data for the manuscript.
Supported byUnited Arab Emirates University UPAR 2022 Research Grant, No. 12S094.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nayla Munawar, PhD, Assistant Professor, Department of Chemistry, College of Science, United Arab Emirates University (UAEU), Al Ain 15551, Abu Dhabi, United Arab Emirates. firstname.lastname@example.org
Received: September 15, 2022 Peer-review started: September 15, 2022 First decision: November 15, 2022 Revised: January 6, 2023 Accepted: March 7, 2023 Article in press: March 7, 2023 Published online: March 21, 2023
Coronavirus disease 2019 (COVID-19) infection caused by the severe acute respiratory syndrome coronavirus 2 virus, its symptoms, treatment, and post-COVID-19 effects have been a major focus of research since 2020. In addition to respiratory symptoms, different clinical variants of the virus have been associated with dynamic symptoms and multiorgan diseases, including liver abnormalities. The release of cytokines by the activation of innate immune cells during viral infection and the high doses of drugs used for COVID-19 treatment are considered major drivers of liver injury in COVID-19 patients. The degree of hepatic inflammation in patients suffering from chronic liver disease and having COVID-19 could be severe and can be estimated through different liver chemistry abnormality markers. Gut microbiota influences liver chemistry through its metabolites. Gut dysbiosis during COVID-19 treatment can promote liver inflammation. Here, we highlighted the bidirectional association of liver physiology and gut microbiota (gut-liver axis) and its potential to manipulate drug-induced chemical abnormalities in the livers of COVID-19 patients.
Core Tip: There are several reviews in the literature focused on the pathophysiology of liver damage during severe acute respiratory syndrome coronavirus 2 infection. However, we highlighted the potential role of gut microbiota in managing drug-induced liver damage during and after coronavirus disease 2019. We shed light on various metabolites produced by gut microorganisms that have a significant role in reducing liver damage in coronavirus disease 2019 with the use of different probiotics and prebiotics.